Literature DB >> 33446173

In the presence of TGF-β1, Asperosaponin VI promotes human mesenchymal stem cell differentiation into nucleus pulposus like- cells.

Yong-Tao Niu1, Lin Xie2, Rong-Rong Deng1, Xiao-Yu Zhang1.   

Abstract

BACKGROUND: The regeneration of nucleus pulposus (NP) cells is an effective method to prevent intervertebral disc degeneration (IVDD). In this study, we investigated the role of Asperosaponin VI (ASA VI), isolated from a traditional Chinese medicine (TCM), the root of Dipsacus asper Wall, in promoting human mesenchymal stem cell (HMSC) proliferation and differentiation into NP-like cells and explored the possible mechanism of action.
METHODS: The effects of ASA VI on HMSC viability and proliferation were determined by the XTT method and EDU staining. Then, Real-time qPCR, immunocytochemistry and immunofluorescence assays were used to measure the effect of ASA VI on the expression of extracellular matrix (ECM) components, such as COL2A1, aggrecan, SOX9, KRT19, PAX1, and glycosaminoglycans (GAGs), in NP cells. In addition, Western blot assay was used to measure the expression of p-ERK1/2 and p-smad2/3.
RESULTS: ASA VI was able to promote the proliferation and differentiation of HMSCs into NP-like cells, and the optimum concentration was 1 mg/L. Western blot assay indicated that the possible mechanism might be related to the activation of p-ERK1 / 2 and p-Smad2 / 3.
CONCLUSIONS: ASA VI can promote the proliferation and differentiation of HMSCs into NP-like cells, which can potentially be used as a treatment for IVDD.

Entities:  

Keywords:  Asperosaponin VI; Differentiation; ERK1/2; Human mesenchymal stem cell; Nucleus pulposus-like cell; smad2/3

Year:  2021        PMID: 33446173     DOI: 10.1186/s12906-020-03169-y

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  51 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

Review 2.  Epidemiology of back disorders: prevalence, risk factors, and prognosis.

Authors:  Nisha J Manek; A J MacGregor
Journal:  Curr Opin Rheumatol       Date:  2005-03       Impact factor: 5.006

3.  Photopolymerizable biogel scaffold seeded with mesenchymal stem cells: safety and efficacy evaluation of novel treatment for intervertebral disc degeneration.

Authors:  Nicholas Vaudreuil; Karl Henrikson; Pedro Pohl; Andrew Lee; Hang Lin; Adam Olsen; Qing Dong; Malcolm Dombrowski; James Kang; Nam Vo; Joon Lee; Gwen Sowa
Journal:  J Orthop Res       Date:  2019-01-16       Impact factor: 3.494

Review 4.  Understanding nucleus pulposus cell phenotype: a prerequisite for stem cell based therapies to treat intervertebral disc degeneration.

Authors:  Hyowon Choi; Zariel I Johnson; Makarand V Risbud
Journal:  Curr Stem Cell Res Ther       Date:  2015       Impact factor: 3.828

5.  Induction of intervertebral disc-like cells from adult mesenchymal stem cells.

Authors:  Eric Steck; Helge Bertram; Rainer Abel; Bohua Chen; Anja Winter; Wiltrud Richter
Journal:  Stem Cells       Date:  2005-03       Impact factor: 6.277

6.  Sports medicine approach to low back pain.

Authors:  Mathew W Lively
Journal:  South Med J       Date:  2002-06       Impact factor: 0.954

Review 7.  Cell-Based Therapies Used to Treat Lumbar Degenerative Disc Disease: A Systematic Review of Animal Studies and Human Clinical Trials.

Authors:  David Oehme; Tony Goldschlager; Peter Ghosh; Jeffrey V Rosenfeld; Graham Jenkin
Journal:  Stem Cells Int       Date:  2015-05-14       Impact factor: 5.443

8.  The chondrodystrophic dog: A clinically relevant intermediate-sized animal model for the study of intervertebral disc-associated spinal pain.

Authors:  Kelly Thompson; Sarah Moore; Shirley Tang; Matthew Wiet; Devina Purmessur
Journal:  JOR Spine       Date:  2018-03-28

9.  Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study.

Authors:  Hemant Kumar; Doo-Hoe Ha; Eun-Jong Lee; Jun Hee Park; Jeong Hyun Shim; Tae-Keun Ahn; Kyoung-Tae Kim; Alexander E Ropper; Seil Sohn; Chung-Hun Kim; Devang Kashyap Thakor; Soo-Hong Lee; In-Bo Han
Journal:  Stem Cell Res Ther       Date:  2017-11-15       Impact factor: 6.832

10.  A novel mouse model of intervertebral disc degeneration shows altered cell fate and matrix homeostasis.

Authors:  Hyowon Choi; Steven Tessier; Elizabeth S Silagi; Rutvin Kyada; Farzad Yousefi; Nancy Pleshko; Irving M Shapiro; Makarand V Risbud
Journal:  Matrix Biol       Date:  2018-03-29       Impact factor: 11.583

View more
  2 in total

Review 1.  Recent Advances in Monitoring Stem Cell Status and Differentiation Using Nano-Biosensing Technologies.

Authors:  Wijin Kim; Eungyeong Park; Hyuk Sang Yoo; Jongmin Park; Young Mee Jung; Ju Hyun Park
Journal:  Nanomaterials (Basel)       Date:  2022-08-25       Impact factor: 5.719

2.  Akebia saponin D protects hippocampal neurogenesis from microglia-mediated inflammation and ameliorates depressive-like behaviors and cognitive impairment in mice through the PI3K-Akt pathway.

Authors:  Qin Liu; Jinqiang Zhang; Chenghong Xiao; Dapeng Su; Liangyuan Li; Changgui Yang; Zhihuang Zhao; Weike Jiang; Zili You; Tao Zhou
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.